All Stories

  1. Emerging role of autologous CD19 CAR T-cell therapies in the second-line setting for large B-cell lymphoma: A game changer?

    Article • Hematology/Oncology and Stem Cell Therapy, November 2022, King Faisal Specialist Hospital and Research Centre - DIGITAL COMMONS JOURNALS

    Hemant Murthy

  2. CT-019 Patient Perceptions of Palliative Care in the Process of Allogenic Stem Cell Transplantation

    Article • Clinical Lymphoma Myeloma & Leukemia, October 2022, Elsevier

    Hemant Murthy

  3. Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy

    Article • Transplantation and Cellular Therapy, October 2022, Elsevier

    Hemant Murthy

  4. MDS-353 Clinical Outcome of Myelodysplastic Syndrome Progressing on Hypomethylating Agents With Evolving Frontline Therapies: Continued Challenges and Unmet Needs

    Article • Clinical Lymphoma Myeloma & Leukemia, October 2022, Elsevier

    Hemant Murthy

  5. The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials

    Article • Transplantation and Cellular Therapy, September 2022, Elsevier

    Hemant Murthy

  6. Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma

    Article • Blood Cancer Journal, July 2022, Springer Science + Business Media

    Hemant Murthy

  7. Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases

    Article • Blood Cancer Journal, July 2022, Springer Science + Business Media

    Hemant Murthy

  8. Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs

    Article • Blood Cancer Journal, June 2022, Springer Science + Business Media

    Hemant Murthy

  9. Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Compl...

    Article • Transplantation and Cellular Therapy, June 2022, Elsevier

    Hemant Murthy

  10. Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation

    Article • Transplantation and Cellular Therapy, June 2022, Elsevier

    Hemant Murthy

  11. Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma

    Article • Blood Cancer Journal, June 2022, Springer Science + Business Media

    Hemant Murthy

  12. Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Compl...

    Article • British Journal of Pharmacology, May 2022, Springer Science + Business Media

    Hemant Murthy

  13. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research

    Article • Transplantation and Cellular Therapy, April 2022, Elsevier

    Hemant Murthy

  14. Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

    Article • British Journal of Pharmacology, March 2022, Springer Science + Business Media

    Hemant Murthy

  15. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors

    Article • JAMA Oncology, March 2022, American Medical Association (AMA)

    Hemant Murthy

  16. Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience

    Article • Leukemia & Lymphoma, February 2022, Taylor & Francis

    Hemant Murthy

  17. Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma

    Article • Clinical Lymphoma Myeloma & Leukemia, February 2022, Elsevier

    Hemant Murthy

  18. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation

    Article • Transplantation and Cellular Therapy, February 2022, Elsevier

    Hemant Murthy

  19. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

    Article • Blood Advances, January 2022, American Society of Hematology

    Hemant Murthy

  20. Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Resear...

    Article • Transplantation and Cellular Therapy, January 2022, Elsevier

    Hemant Murthy

  21. Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?

    Article • Radiotherapy and Oncology, January 2022, Elsevier

    Hemant Murthy

  22. Management of CAR T-cell related toxicities: What did the learning curve teach us so far?

    Article • Hematology/Oncology and Stem Cell Therapy, January 2022, King Faisal Specialist Hospital and Research Centre - DIGITAL COMMONS JOURNALS

    Hemant Murthy

  23. A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients

    Article • British Journal of Pharmacology, November 2021, Springer Science + Business Media

    Hemant Murthy

  24. Comparative study of therapy‐related and de novo adult b‐cell acute lymphoblastic leukaemia

    Article • British Journal of Haematology, October 2021, Wiley

    Hemant Murthy

  25. Omission of day +11 methotrexate dose and allogeneic hematopoietic cell transplantation outcomes: results of a systematic review/meta-analysis

    Article • British Journal of Pharmacology, October 2021, Springer Science + Business Media

    Hemant Murthy

  26. Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: What is the evidence?

    Article • Hematology/Oncology and Stem Cell Therapy, October 2021, King Faisal Specialist Hospital and Research Centre - DIGITAL COMMONS JOURNALS

    Hemant Murthy

  27. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

    Article • British Journal of Pharmacology, September 2021, Springer Science + Business Media

    Hemant Murthy

  28. Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH‐based algorithm distinguishes prognostic groups and outcomes

    Article • Blood Cancer Journal, September 2021, Springer Science + Business Media

    Hemant Murthy

  29. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood ...

    Article • Haematologica, August 2021, Ferrata Storti Foundation (Haematologica)

    Hemant Murthy, Dr Satiro N De Oliveira

  30. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era

    Article • Leukemia, June 2021, Springer Science + Business Media

    Hemant Murthy

  31. The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic

    Article • Transplantation and Cellular Therapy, June 2021, Elsevier

    Hemant Murthy

  32. Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation

    Article • British Journal of Pharmacology, May 2021, Springer Science + Business Media

    Hemant Murthy

  33. Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation

    Article • Transplantation and Cellular Therapy, May 2021, Elsevier

    Hemant Murthy

  34. Systematic Reviews in Hematopoietic Cell Transplantation and Cellular Therapy: Considerations and Guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and Center for Interna...

    Article • Transplantation and Cellular Therapy, May 2021, Elsevier

    Hemant Murthy

  35. Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation

    Article • British Journal of Pharmacology, April 2021, Springer Science + Business Media

    Hemant Murthy

  36. Impact of hypoalbuminemia on the prognosis of relapsed/refractory B‐cell lymphoma treated with axicabtagene ciloleucel

    Article • European Journal Of Haematology, April 2021, Wiley

    Hemant Murthy

  37. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era

    Article • Leukemia, March 2021, Springer Science + Business Media

    Hemant Murthy

  38. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation

    Article • Blood Cancer Journal, March 2021, Springer Science + Business Media

    Hemant Murthy

  39. Efficacy of allogeneic hematopoietic cell transplantation in patients with chronic phase CML resistant or intolerant to tyrosine kinase inhibitors

    Article • Hematology/Oncology and Stem Cell Therapy, March 2021, King Faisal Specialist Hospital and Research Centre - DIGITAL COMMONS JOURNALS

    Hemant Murthy

  40. Broad-Spectrum Antibiotics and Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Transplantation for Acute Leukemia: Association of Carbapenem Use with the Risk of Acute Graft-versus-Host Disease

    Article • Transplantation and Cellular Therapy, February 2021, Elsevier

    Hemant Murthy

  41. Systematic Review/Meta-Analysis on Efficacy of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease: An International Effort on Behalf of the Pediatric Diseases Working Party of European Society for Blood and Marrow Transplantation and ...

    Article • Transplantation and Cellular Therapy, February 2021, Elsevier

    Hemant Murthy

  42. Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023

    Article • Transplantation and Cellular Therapy, February 2021, Elsevier

    Hemant Murthy

  43. Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for Int...

    Article • British Journal of Pharmacology, January 2021, Springer Science + Business Media

    Hemant Murthy

  44. Primary peritoneal myeloid sarcoma in association with CBFB/MYH11 fusion

    Article • Leukemia Research Reports, January 2021, Elsevier

    Hemant Murthy

  45. Autologous Hematopoietic Cell Transplantation

    Article • December 2020, Springer Publishing Company

    Hemant Murthy

  46. Pre-Transplant Marital Status and Hematopoietic Cell Transplantation Outcomes

    Article • December 2020, MDPI AG

    Hemant Murthy

  47. Real‐world experience of carfilzomib‐associated cardiovascular adverse events: SEER‐Medicare data set analysis

    Article • Cancer Medicine, November 2020, Wiley

    Hemant Murthy

  48. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes

    Article • Biology of Blood and Marrow Transplantation, November 2020, Elsevier

    Hemant Murthy

  49. Baseline Gut Microbiota Composition Is Associated with Major Infections Early after Hematopoietic Cell Transplantation

    Article • Biology of Blood and Marrow Transplantation, November 2020, Elsevier

    Hemant Murthy

  50. Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials

    Article • Current Research in Translational Medicine, November 2020, Elsevier

    Hemant Murthy

  51. Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma

    Article • British Journal of Haematology, October 2020, Wiley

    Hemant Murthy

  52. Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis

    Article • Clinical Lymphoma Myeloma & Leukemia, October 2020, Elsevier

    Hemant Murthy

  53. African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States

    Article • Cancer, September 2020, Wiley

    Hemant Murthy

  54. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma

    Article • Cancer, September 2020, Wiley

    Hemant Murthy

  55. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide

    Article • Biology of Blood and Marrow Transplantation, August 2020, Elsevier

    Hemant Murthy

  56. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report

    Article • Blood Advances, July 2020, American Society of Hematology

    Hemant Murthy

  57. Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant

    Article • JAMA Oncology, July 2020, American Medical Association (AMA)

    Hemant Murthy

  58. Correction: Impact of autologous blood transfusion after bone marrow harvest on unrelated donor’s health and outcome: a CIBMTR analysis

    Article • British Journal of Pharmacology, June 2020, Springer Science + Business Media

    Hemant Murthy

  59. Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors

    Article • Biology of Blood and Marrow Transplantation, June 2020, Elsevier

    Hemant Murthy

  60. Dietary Intake and Diet Quality of Hematopoietic Stem Cell Transplantation Survivors

    Article • Biology of Blood and Marrow Transplantation, June 2020, Elsevier

    Hemant Murthy

  61. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases

    Article • Blood Advances, May 2020, American Society of Hematology

    Hemant Murthy

  62. Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research

    Article • Biology of Blood and Marrow Transplantation, March 2020, Elsevier

    Hemant Murthy

  63. Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield

    Article • Blood Advances, February 2020, American Society of Hematology

    Hemant Murthy

  64. Fatal Mycobacterium abscessus in a recipient of axicabtagene ciloleucel CAR-T: beware of T cells

    Article • British Journal of Pharmacology, January 2020, Springer Science + Business Media

    Hemant Murthy

  65. Corrigendum to ‘Efficacy of allogeneic HCT in HTLV-1 associated adult T-cell leukemia/lymphoma: results of a systematic review/meta-analysis’ [Biology of Blood and Marrow Transplantation 25/8 (2019) 1695-1700]

    Article • Biology of Blood and Marrow Transplantation, January 2020, Elsevier

    Hemant Murthy

  66. Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis

    Article • Biology of Blood and Marrow Transplantation, January 2020, Elsevier

    Hemant Murthy

  67. Cytokine Release Syndrome: Current Perspectives

    Article • ImmunoTargets and Therapy, October 2019, Taylor & Francis

    Hemant Murthy

  68. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood ...

    Article • Haematologica, September 2019, Ferrata Storti Foundation (Haematologica)

    Hemant Murthy, Dr Satiro N De Oliveira

  69. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide–Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma

    Article • Biology of Blood and Marrow Transplantation, September 2019, Elsevier

    Hemant Murthy

  70. Efficacy of Allogeneic Hematopoietic Cell Transplantation in Human T Cell Lymphotropic Virus Type 1–Associated Adult T Cell Leukemia/Lymphoma: Results of a Systematic Review/Meta-Analysis

    Article • Biology of Blood and Marrow Transplantation, August 2019, Elsevier

    Hemant Murthy

  71. The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time

    Article • Biology of Blood and Marrow Transplantation, July 2019, Elsevier

    Hemant Murthy

  72. A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients

    Article • Blood Advances, June 2019, American Society of Hematology

    Hemant Murthy

  73. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission

    Article • Blood Advances, June 2019, American Society of Hematology

    Hemant Murthy

  74. Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades

    Article • Biology of Blood and Marrow Transplantation, June 2019, Elsevier

    Hemant Murthy

  75. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis

    Article • Journal of Hematology & Oncology, January 2019, Springer Science + Business Media

    Hemant Murthy

  76. Allogeneic Hematopoietic Cell Transplantation Is an Effective Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm in First Complete Remission: Systematic Review and Meta-analysis

    Article • Clinical Lymphoma Myeloma & Leukemia, November 2018, Elsevier

    Hemant Murthy

  77. Abstract 3253: Droplet digital PCR is a sensitive method for detecting refractory acute myeloid leukemia (AML) clones in peripheral blood and saliva

    Article • Cancer Research, July 2018, American Association for Cancer Research (AACR)

    Hemant Murthy

  78. Pharmacokinetic and clinical outcomes when ideal body weight is used to dose busulfan in obese hematopoietic stem cell transplant recipients

    Article • British Journal of Pharmacology, June 2018, Springer Science + Business Media

    Hemant Murthy

  79. Clinical factors influencing engraftment in patients with non-Hodgkin lymphoma following autologous stem cell transplant.

    Article • Journal of Clinical Oncology, May 2018, American Society of Clinical Oncology (ASCO)

    Hemant Murthy

  80. Platelet count and transfusion dependence as prognostic factors of engraftment in autologous stem cell transplantation.

    Article • Journal of Clinical Oncology, May 2018, American Society of Clinical Oncology (ASCO)

    Hemant Murthy

  81. iCare 1: A prospective clinical trial to predict treatment response based on genomics-informed computational biology in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

    Article • Journal of Clinical Oncology, May 2018, American Society of Clinical Oncology (ASCO)

    Hemant Murthy

  82. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis

    Article • Blood Advances, April 2018, American Society of Hematology

    Hemant Murthy

  83. Thyroid dysfunction in adult hematopoietic cell transplant survivors: risks and outcomes

    Article • British Journal of Pharmacology, February 2018, Springer Science + Business Media

    Hemant Murthy

  84. Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study

    Article • Biology of Blood and Marrow Transplantation, February 2018, Elsevier

    Hemant Murthy

  85. Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score

    Article • British Journal of Haematology, January 2018, Wiley

    Hemant Murthy

  86. Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features

    Article • Case Reports in Hematology, January 2018, Hindawi Publishing Corporation

    john wingard, Hemant Murthy

  87. A rare presentation of hemophagocytic lymphohistiocytosis in a patient with untreated chronic lymphocytic leukemia: A case report and review of the literature

    Article • Hematology and Leukemia, January 2018, Herbert Publications PVT LTD

    Hemant Murthy

  88. Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia

    Article • Blood Cancer Journal, November 2017, Springer Science + Business Media

    Hemant Murthy

  89. Frailty: the missing piece of the pre- hematopoietic cell transplantation assessment?

    Article • British Journal of Pharmacology, October 2017, Nature

    Aparna Hegde, Hemant Murthy

  90. Diagnosis and Management of Leukemic and Lymphomatous Meningitis

    Article • Cancer Control, January 2017, SAGE Publications

    Hemant Murthy

  91. Plasma Cell Myeloma With Very High Ki67 Proliferation Rate: Comparison of Visual Estimation and Computational Image Analysis With Description of Clinical and Pathologic Features

    Article • American Journal of Clinical Pathology, October 2015, Oxford University Press (OUP)

    Hemant Murthy

  92. The Value of Patient Reported Outcomes and Other Patient-Generated Health Data in Clinical Hematology

    Article • Current Hematologic Malignancy Reports, June 2015, Springer Science + Business Media

    Hemant Murthy

  93. Autologous Bone Marrow Transplantation

    Article • Springer Publishing Company

    Hemant Murthy

  94. Allogeneic Bone Marrow Transplantation

    Article • Springer Publishing Company

    Hemant Murthy